# Treadwell Therapeutics

Source: https://onco.cc/companies/treadwell-therapeutics/  
OnCo record `treadwell-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Treadwell Therapeutics is a Hong Kong-based biotechnology company running 3 late-stage cancer trials of CFI-402411, CFI-400945 and CFI-402257 in acute myeloid leukaemia, myelodysplastic syndromes / neoplasms and HR-positive / HER2-negative breast cancer.

## Summary

Treadwell Therapeutics, based in Hong Kong, Hong Kong, is a biotechnology company. Treadwell Therapeutics is a clinical-stage, multi-modality oncology company developing small molecules, biologics and T-cell receptor therapies against novel cancer targets. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials, testing CFI-402411, CFI-400945 and CFI-402257 in acute myeloid leukaemia, myelodysplastic syndromes / neoplasms and HR-positive / HER2-negative breast cancer. The largest, NCT04521413 (Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies), plans to enrol 170 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Treadwell Therapeutics, Inc
- Tags: ctgov-sponsor
- HQ: Hong Kong
- Type: biotech
- Website: https://treadwelltx.com

## Sources

- Official website: https://treadwelltx.com
- ClinicalTrials.gov: trials led by Treadwell Therapeutics: https://clinicaltrials.gov/search?lead=Treadwell%20Therapeutics%2C%20Inc
- Pipeline page: https://treadwelltx.com/pipeline/

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- trials: [A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML](https://onco.cc/trials/nct04730258/), [CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer](https://onco.cc/trials/nct05251714/), [Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies](https://onco.cc/trials/nct04521413/)

---
JSON: https://onco.cc/api/v1/entities/treadwell-therapeutics.json